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Vasopeptidase inhibitor restores the balance of vasoactive hor-
mones in progressive nephropathy.
Background. The mechanism(s) underlying greater reno-
protection of combined blockade of angiotensin-converting
enzyme (ACE) and neutral endopeptidase (NEP) by vasopep-
tidase over ACE inhibitors are ill defined. We previously found
that progressive renal disease is associated with increased renal
synthesis of endothelin-1 (ET-1) in the face of reduced gener-
ation of renal nitric oxide (NO) in the remnant kidney model.
Here we compared changes in urinary excretion of ET-1 and
nitrite/nitrate, markers of renal ET-1, and NO synthesis, re-
spectively, and urinary cGMP, an indirect index of renal atrial
natriuretic peptide (ANP) synthesis, after administration of va-
sopeptidase or ACE inhibitor in rats with renal mass reduction
(RMR).
Methods. Twenty-one days after 5/6 nephrectomy, after the
onset of hypertension and overt proteinuria, rats were divided
in 3 groups (N = 7–8) and given daily by gavage: vehicle, the
vasopeptidase inhibitor AVE7688 (3 mg/kg bid), or enalapril
(5 mg/kg bid) until day 90. Normal rats (N = 5) served as control
rats.
Results. Systolic blood pressure in RMR rats was equally con-
trolled by AVE7688 and enalapril. AVE7688 resulted in a sig-
nificant antiproteinuric effect, with urinary protein levels being
reduced on average by 83% in respect to vehicle (88 ± 28 vs.
518 ± 27 mg/day, P < 0.0001). Enalapril achieved a 47% reduc-
tion in proteinuria (277 ± 81 mg/day, P < 0.01 vs. vehicle) to
levels that remained higher (P < 0.01), however, than those af-
ter AVE7688. Renal function impairment and glomerular and
tubular changes were significantly (P < 0.05 vs. vehicle) amelio-
rated by AVE7688, and partially affected by enalapril. AVE7688
reduced the abnormal urinary excretion of ET-1 of RMR ani-
mals (98 ± 8 vs. vehicle: 302 ± 50 pg/24h, P < 0.001) more than
enalapril (159 ± 14 pg/24h, P < 0.05 vs. AVE7688). Consistently,
AVE7688 was more effective than enalapril in augmenting renal
synthesis of NO (2487 ± 267 and 1519 ± 217 vs. vehicle: 678 ± 71
nmol/15 h; P < 0.001, AVE7688 vs. vehicle, P < 0.01 AVE7688
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vs. enalapril). AVE7688 significantly increased urinary cGMP
(78 ± 6 vs. vehicle 45 ± 9 nmol/24h; P < 0.01).
Conclusion. The superior renoprotection achieved by
AVE7688 over enalapril in progressive renal injury is due to the
correction of the altered balance of vasoconstrictor/vasodilator
mediators in the kidney.
The vasopeptidase inhibitors, initially targeted for the
treatment of hypertension and heart failure [1, 2], are
being evaluated for other indications, including renal dis-
eases that are not completely responsive to angiotensin-
converting enzyme (ACE) inhibitors [3]. Vasopeptidase
inhibitors display a dual mechanism of action, and in-
hibit the activity of ACE and neutral endopeptidase
(NEP) with a single molecule [1, 2]. ACE and NEP
are membrane-bound zinc-containing metallopeptidases
with a widespread distribution in the vascular endothe-
lium, smooth muscle cells, and the brush border of tubular
cells. Both enzymes share a number of common sub-
strates, including angiotensin I, bradykinin, enkephalins,
and chemotactic peptides. NEP also degrades natriuretic
peptides and contributes to the formation/degradation
of endothelin-1 (ET-1) [4]. By simultaneously inhibiting
the renin-angiotensin system and potentiating natriuretic
peptide activity, vasopeptidase inhibitors may reduce
vasoconstrictor and proliferative mediators, such as an-
giotensin II and ET-1, and increase local levels of va-
sodilator atrial natriuretic peptide (ANP) and bradykinin
and, secondarily, nitric oxide (NO) [5], since bradykinin
is a potent stimulator of NO release [6].
After removal of a critical number of nephrons, adap-
tive hemodynamic changes in the remaining ones—
which include hyperfiltration and hypertension—ensure
enough filtration power to the kidney, but are ultimately
detrimental [7]. Glomerular hypertension, which follows
angiotensin II–dependent efferent arteriole vasoconstric-
tion, reduces the size selective function of the glomeru-
lar barrier, which in turn enhances protein ultrafiltration.
ACE inhibitors limit glomerular hypertension and
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proteinuria, thus retarding renal injury in animals and
humans. In rats with surgical reduction of renal mass
(RMR), which mimics the human condition of nephron
loss, ACE inhibition is fully effective when the treatment
is started soon after surgery [8, 9], but renoprotection is
only partial when animals are given ACE inhibitor at an
advanced phase of the disease [10]. Short-term studies in
rats with RMR have demonstrated some improvement
in renal function with the use of inhibitors of NEP, such
as phosphoramidon, whose beneficial effect has been at-
tributed to the prolongation of the half lives of vasoactive
peptides and kinins [11]. In the same model, combined
blockade of ACE and NEP by vasopeptidase inhibitors
afforded greater renoprotection than the sole inhibition
of ACE [12] on account of their capacity of more effec-
tively lowering glomerular capillary pressure [10]. The
biochemical mediators of this effect are still ill defined.
We previously found that surgical reduction of renal
mass is associated with excessive renal generation of ET-
1 in the face of less NO production [13–15]. Imbalance
between vasoconstrictor and vasodilator mediators could
account for altered glomerular hemodynamics and con-
tribute to intraglomerular capillary hypertension [16, 17].
Correcting the abnormal ET-1/NO ratio by specific ther-
apies based either on the use of an ET-1 receptor antag-
onist or L-arginine/NO donor limits the progression of
renal disease in the remnant kidney [16, 17]. The reno-
protective effect of ACE inhibitors was also attributed to
the partial amelioration of ET-1/NO imbalance [17].
Here we sought to compare the antihypertensive and
renoprotective effects of the vasopeptidase inhibitor
AVE7688 versus the ACE inhibitor enalapril in rats with
remnant kidney starting treatments when animals had
overt nephropathy. Whether the possible superior reno-
protection achieved by the vasopeptidase inhibitor could
be attributable to changes in renal synthesis of vasocon-
strictor versus vasodilator substances was also assessed.
METHODS
Experimental design
Male Sprague-Dawley rats (Charles River Italia S.p.A.,
Calco, Italy) with initial body weights of 300 to 350 g
were used in this study. Animal care and treatment were
conducted in accordance with the institutional guidelines
that are in compliance with national (Decreto Legislativo
n.116, Gazzetta Ufficiale suppl 40, 18 febbraio 1992, Cir-
colare n.8, Gazzetta Ufficiale, 14 luglio 1994) and interna-
tional laws and policies (EEC Council Directive 86/609,
OJL358-1, December 1987; Guide for the Care and Use
of Laboratory Animals, U.S. National Research Coun-
cil, 1996). All animals were housed in a room in which
the temperature was kept constant on a 12-hour dark/12-
hour light cycle, and allowed free access to standard diet
containing 20% protein by weight and tap water. RMR
was obtained by right nephrectomy and ligation of 2 or 3
branches of the main renal artery, according to Olson et
al [18]. Twenty-one days after surgery, when animals had
hypertension and overt proteinuria, they were divided in
3 groups, and the following were administered daily by
gavage. Group 1 (N = 7) received vehicle (methylcellu-
lose 0.5%, bid). Group 2 (N = 8) received AVE 7688 (7-
[[(2S)-2-(acetylthio)-1-oxo-methylpropyl] amino]–1,2,3,
4,6,7,8,12 b-octahydro-6-oxo-,(4S,7S12bR)-pyridol[2,1-
a][2]benzapin-4-carboxyacid) (Aventis Pharma Deutsch-
land GmbH, Frankfurt am Main, Germany) [19] at the
dose of 3 mg/kg bid. The ACE inhibitor enalapril was ad-
ministered at the dose of 5 mg/kg bid [10] (group 3, N =
8). Treatments lasted until day 90. An additional group
of normal rats (group 4, N = 5) without any therapy was
followed for the same period and served as control rats.
By a preliminary study in rats with RMR, we chose the
dose of AVE7688 to control blood pressure to a similar
extent as enalapril (5 mg/kg bid). The dose of AVE7688
was found to be 3 mg/kg bid.
In all groups, systolic blood pressure, urinary protein
excretion, and serum creatinine levels were monitored
during the study. Urinary excretion of ET-1, which likely
reflects the renal synthesis of the peptide [13], was as-
sessed at the end of the study. To obtain an indirect in
vivo index of renal NO synthesis, the urinary excretion of
nitrites/nitrates (NO2−/NO3−), the stable NO metabo-
lites, was measured 90 days after surgery. To avoid di-
etary NO3− intake, rats were fasted overnight and given
distilled water to drink. Metabolic cages were cleaned
with a germicidal soap to prevent NO2−/NO3− forma-
tion by bacteria [15]. Urinary excretion of cyclic guano-
sine monophosphate (cGMP), which reflects ANP renal
synthesis [20], was also measured at day 90. At the end
of the study, rats were anesthetized and kidneys were re-
moved for morphologic analysis.
Systolic blood pressure (SBP) was recorded by tail
plethysmography in conscious rats. Twenty-four–hour
urine samples were collected using metabolic cages, and
proteinuria was determined by modified Coomassie blue
G dye-binding assay for proteins with bovine serum al-
bumin as standard [21]. Blood was collected from the tail
vein of anesthetized animals. Serum was obtained after
whole blood clotting and kept frozen at −20◦C until as-
sayed. Serum creatinine was measured using an autoana-
lyzer (CX5; Beckman Instruments, Fullerton, CA, USA).
Urinary ET-1 measurement
Urinary ET-1 levels were evaluated by radioim-
munoassay (RIA) after extraction with Sep-pak C18 (Wa-
ters; Milford, MA, USA) as previously described [13].
Cross-reactivity of the ET-1 antibody (Peninsula Labo-
ratories, Inc., San Carlos, CA, USA) was as follows: ET-2,
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46.9%; ET-3, 17%; and big-ET-1, 9.4%. Results, corrected
for the recovery, were expressed as pg/day.
Urinary nitrites/nitrates
NO2−/NO3− were measured using a high-performance
liquid chromatograph (HPLC System Gold; Beckman In-
struments, Inc.). Urine samples were treated with zinc
sulfate (60 lmol/L, final concentration), and centrifuged
to eliminate proteins. Supernatants were eluted into a
Dowex AG 50 WX-8 column (Bio-Rad, Hercules, CA,
USA) followed by a cadmium column that catalyzes
the reduction of nitrate to nitrite (eluent borate buffer,
pH 8.5). The post-column eluate reacted with Griess
reagent [1% sulphanylic acid in 5% H3PO4, 0.1% of N-
(1-naphthyl)-ethylenediamine, vol:vol] to form a purple
azo dye, and the color was analyzed at k = 504 nm. Val-
ues were extrapolated from a standard curve and cor-
rected for recovery, which averaged 90% as determined
by addition of known amounts of standard nitrate to an
additional portion of each sample [15].
Urinary cGMP excretion
Urinary cGMP levels were determined by commercial
enzyme immunoassay (EIA) kit (range 0.5–128 pmol/L;
Amersham Pharmacia Biotech, Buckinghamshire, UK).
Data were expressed as nmol/24h.
Renal histology
The removed kidneys were fixed overnight in Dubosq-
Brazil, dehydrated in alcohol, and embedded in paraffin.
Kidney samples were sectioned at 3-lm intervals, and
the sections were stained with Masson’s trichrome, hema-
toxylin and eosin, and periodic-acid Schiff reagent (PAS
stain). Tubular (atrophy, casts, and dilatation) and inter-
stitial changes (fibrosis and inflammation) were graded
from 0 to 4+ (0, no changes; 1+, changes affecting less
than 25% of the sample; 2+, changes affecting 25% to
50% of the sample; 3+, changes affecting 50% to 75%
of the sample; 4+, changes affecting 75% to 100% of
the sample). At least 100 glomeruli were examined for
each animal, and the extent of glomerular damage was
expressed as the percentage of glomeruli presenting scle-
rotic lesions. All renal biopsies were analyzed at the same
time by the same pathologist, who was unaware of the
group assignment of individual rats.
Statistical analysis
Data are expressed as mean ± SE. The analysis of
covariance (ANCOVA) was used for log-transformed
proteinuria, which allowed the inclusion of proteinuria
measured at day 21 (baseline) as a covariate in the model,
followed by Bonferroni’s adjustment for multiple com-
parisons. For vasoactive mediators, the data were log
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Fig. 1. Time course of systolic blood pressure (SBP) in rats with renal
mass reduction (RMR) administered vehicle, AVE7688 (3 mg/kg bid),
or enalapril (5 mg/kg bid). Treatments started 21 days after surgical
ablation, when RMR rats developed hypertension (P < 0.01 vs. control).
Data are mean ± SE. ∗∗P < 0.01, both drug treatments vs. vehicle; #P <
0.05, both drug treatments vs. control.
transformed and analyzed by the univariate analysis of
variance (univariate ANOVA). All the other data were
analyzed using the nonparametric Kruskal-Wallis test fol-
lowed by Ryan’s procedure for multiple comparisons. The
statistical significance level was defined as P < 0.05.
RESULTS
Systemic parameters
By the end of the study, 2 rats with RMR died in each
of the groups treated with vehicle and AVE7688; 1 died in
the group given enalapril. Food intake was comparable in
RMR and control rats for the entire study period. RMR
rats gained weight in a similar manner, and at the end
of the study, body weight values were comparable in all
treatment groups (vehicle, 527 ± 30 g; AVE7688, 557 ±
16 g; enalapril, 548 ± 16 g). Body weights of control rats
were numerically higher than those of RMR rats (655 ±
44 g), although a statistical significance was not reached.
The time course of SBP is shown in Figure 1. Before
the start of treatments (day 21), rats with RMR exhibited
a significant (P < 0.01) higher SBP compared to control
rats (159 ± 5 vs. 105 ± 5 mm Hg). In rats given vehi-
cle, hypertension remained sustained along the study pe-
riod (183 ± 5 mm Hg). Treatments with AVE 7688 and
enalapril controlled SBP to levels significantly (P < 0.05)
lower than control rats (101 ± 3 and 109 ± 3 vs. 118 ±
5 mm Hg).
Renal parameters
At day 21, RMR rats had overt proteinuria that aver-
aged 88 ± 7 mg/day (P < 0.05 vs. control rats). A further
and progressive increase in urinary protein excretion was
observed over time in the vehicle group, with values
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Fig. 2. Urinary protein excretion and serum creatinine at day 90 in rats
with RMR treated from day 21 after surgery with vehicle, AVE7688, or
enalapril. Data are mean ± SE. P < 0.01, P < 0.0001 vs. vehicle;
$P < 0.01 vs. enalapril.
reaching 518 ± 27 mg/day at the end of the study (Fig. 2).
AVE7688 afforded a significant antiproteinuric effect, re-
sulting in an 83% reduction of protein levels compared
to vehicle (88 ± 28 mg/day, P < 0.0001). Treatment with
enalapril also led to a 47% decrease in proteinuria with
respect to vehicle (277 ± 81 mg/day, P < 0.01). Over-
all, AVE7688 was more antiproteinuric as compared to
enalapril, with urinary protein excretion levels signifi-
cantly (P < 0.01) lower than that in enalapril-treated
animals.
Renal function was impaired in RMR rats given ve-
hicle, as indicated by a significant (P < 0.01) elevation
in serum creatinine levels as compared with control rats
(1.8 ± 0.4 vs. 0.6 ± 0.01 mg/dL) (Fig. 2). The vasopepti-
dase inhibitor significantly (P < 0.01) decreased serum
creatinine levels (0.9 ± 0.04 mg/dL), whereas in rats ad-
ministered enalapril, values (1.4 ± 0.2 mg/dL) were only
numerically lower than those in the vehicle group.
Renal histology
The results of renal morphologic analysis performed
at day 90 are shown in Table 1. RMR rats given vehi-
cle showed sclerotic changes affecting 50% of glomeruli
on average. Tubulointerstitial lesions consisted of lumi-
nal proteinaceous casts, tubular atrophy, and interstitial
inflammation and fibrosis. Administration of AVE7688
was associated with a significant (P < 0.05) reduction in
the percentage of glomeruli with sclerotic changes, as well
as in the scores of tubular damage. Enalapril treatment
partially reduced glomerular and tubular changes, albeit
not to a statistically significant extent.
Renal synthesis of vasoactive mediators
Urinary excretion of ET-1 was 5-fold increased in RMR
rats given vehicle over control rats at day 90 (302 ± 50 vs.
65 ± 9 pg/24h, P < 0.001) (Fig. 3). Treatment with AVE
7688 lowered urinary excretion of ET-1 by 68% (98 ±
Table 1. Effect of AVE7688 and enalapril on renal morphology in
rats with renal mass reduction
Glomerulosclerosis (%) Tubular damage (score)
RMR
Vehicle 50.4 ± 7.9 1.8 ± 0.4
AVE7688 11.6 ± 6.1a 0.5 ± 0.2a
Enalapril 37.1 ± 10.7 1.3 ± 0.3
Control 1.8 ± 0.4 0.2 ± 0.2
Values are mean ± SE.
aP < 0.05 vs. vehicle.
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Fig. 3. Urinary excretion of endothelin-1 (ET-1) at day 90 in rats with
RMR from day 21 after surgery given vehicle, AVE7688, or enalapril.
Data are mean ± SE. ∗P < 0.01 and ∗∗P < 0.001 vs. vehicle; ◦P < 0.05
vs. enalapril.
8 pg/24h, P < 0.001 vs. vehicle), which rendered absolute
values similar to healthy control rats. Enalapril induced a
47% reduction of urinary ET-1 (159 ± 14 pg/24h, P < 0.01
vs. vehicle). Levels of urinary ET-1 after enalapril were
higher, however, than those after AVE7688 (P < 0.05).
Consistent with previous studies [15], renal NO pro-
duction, as indirectly evaluated by measurement of uri-
nary excretion of NO2−/NO3−, was reduced in rats with
RMR given vehicle in respect to control rats (678 ± 71
vs. 3892 ± 625 nmol/15h, P < 0.001) (Fig. 4A). The reno-
protection conferred by the vasopeptidase inhibitor was
associated with significantly (P < 0.001) increased lev-
els of NO metabolites in the urine (2487 ± 267 nmol/15
h) with respect to vehicle. Enalapril administration re-
sulted in an increase in urinary nitrites/nitrates (1519 ±
217 nmol/15h, P < 0.01 vs. vehicle) with levels that were
significantly (P < 0.05) lower than those after AVE7688.
Urinary excretion of cGMP, taken as an index of re-
nal ANP activity, was significantly (P < 0.001) decreased
in RMR rats compared to control rats (45 ± 9 vs. 118 ±
8 nmol/24h) (Fig. 4B). AVE7688 significantly increased
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Fig. 4. Urinary excretion of NO2−/NO3− (A) and of cyclic guanosine
monophosphate (cGMP) (B) measured at day 90 in rats with renal
mass reduction from day 21 after surgery given vehicle, AVE7688, or
enalapril. Data are mean ± SE. ∗P < 0.01 and ∗∗P < 0.001 vs. vehicle;
◦P < 0.05 vs. enalapril.
urinary cGMP (78 ± 6 nmol/24h, P < 0.01 vs. vehi-
cle), whereas enalapril had a rather weak effect (58 ±
5 nmol/24h).
DISCUSSION
Reduction in proteinuria is an important goal in
the treatment of chronic nephropathies [3]. Clinical
trials—both in diabetic and nondiabetic proteinuric
nephropathies—found that angiotensin II blockers pre-
dictably slow glomerular filtration rate (GFR) decline
rate, and limit progression to end-stage renal diseases
to the extent that they lower urinary proteins [22, 23].
However, ACE inhibitors alone are not uniformly ef-
fective in all patients, and their capacity to lower pro-
teinuria and disease progression is moreover limited in
those with advanced disease. Drugs that provide addi-
tional renoprotection are urgently needed. Here we com-
pared the effect of the vasopeptidase inhibitor AVE7688
with that of the ACE inhibitor enalapril in the hyperten-
sive 5/6 nephrectomy rat model, started late in the course
of the disease, on renal function and structure. To rule
out that possible long-term renoprotective effects were
associated with different ability of the 2 drugs to lower
systolic blood pressure, doses achieving equally antihy-
pertensive effects were employed. The results demon-
strated that AVE7688 maintained significantly lower
levels of proteinuria than did enalapril, which would
suggest that the additional benefit obtained with the
vasopeptidase inhibitor was due to the activity of the
molecule, rather than to its effect on blood pressure. Nev-
ertheless, enalapril displayed a significant effect, afford-
ing a 47% reduction in proteinuria, which is in the range
of urinary protein reduction considered clinically rele-
vant in humans. In a previous study in subtotal nephrec-
tomized rats, omapatrilat lowered proteinuria better than
fosinopril, but renal function and structure at the end of
12 weeks of treatment were comparable [12]. However,
the doses of vasopeptidase inhibitor and ACE inhibitor
employed were not chosen to give comparable blood
pressure levels [12]. When systemic blood pressure was
equally controlled, omapatrilat, besides allowing supe-
rior reduction of proteinuria than enalapril, better pro-
tected the kidney from injury and delayed progression
[10]. The greater renoprotection by the vasopeptidase in-
hibitor was attributed to the greater lowering of glomeru-
lar capillary pressure, but the involvement of vasoactive
mediators, whose specific roles were not defined in that
work, was also suggested.
Among vasoconstrictors, ET-1 has been recognized as
playing a role in the process of progressive renal injury in
chronic renal diseases [24]. Thus, pharmacologic manip-
ulation of the ET-1 pathway retarded the rate at which
renal function was lost [25], and also prolonged survival
of RMR rats [26]. Furthermore, the renoprotective effect
of the endothelin receptor antagonist was associated with
increased renal NO generation, suggesting that excessive
renal ET-1 release in RMR rats, besides being noxious,
per se, could be responsible, at least in part, for the de-
fective renal NO availability [16]. On the other hand, NO
may, in turn, limit the ET-1 synthesis, as documented by
the prolongation of lifespan in RMR rats after NO donor,
which was accompanied by reduction of the abnormal re-
nal synthesis of ET-1 [17]. Altogether, these data support
the notion of a reciprocal regulation between ET-1 and
NO, and indicate that the correction of the imbalance
between vasoconstrictors and vasodilators could be one
of the mechanisms responsible for the protection from
the development of kidney damage. A major finding of
the present study is the observation that the vasopepti-
dase inhibitor modulated the renal synthesis of ET-1 and
NO. Thus, AVE7688 inhibited the exaggerated synthe-
sis of ET-1 in the kidney, an effect shared by enalapril,
although to a lesser extent. The capability of ACE in-
hibitors to interfere with renal ET-1 synthesis has been
widely reported in RMR rats [17, 27, 28], with the effi-
cacy of this drug class depending on the compound used,
as well as the time at which treatment was started. The ef-
fect of AVE7688 on ET-1 was rather unexpected given the
apparent opposite actions of ACE and NEP inhibition on
the synthetic rate of the peptide. While ACE inhibition
reduces ET-1 renal production, NEP blockade should
theoretically impede ET-1 breakdown—mainly sustained
by the neutral endopeptidase 24.11—with the net provi-
sional result of unchanged renal ET-1. However, recent
studies have indicated that NEP could also contribute to
the formation of ET-1 from its precursor Big ET-1 [2].
The final step of post-translational processing of ET-1
is catalyzed by a family of zinc-metalloproteases termed
endothelin-converting enzymes (ECE), which share a
37% aminoacid sequence identity with NEP, specifically
around the catalytic centers of the molecules [29]. NEP
inhibition does modulate the activity of ECE, as reported
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in experimental atherosclerosis, in which reduced con-
version of Big ET-1 to active ET-1 via ECE resulted in
decreased ET-1 concentration in aortic tissue from rab-
bits chronically treated with a NEP inhibitor [4]. On the
other hand, attenuated ECE-1 activity by NEP inhibition
resulted in augmentation of circulating ANP [4], which, in
turn, could inhibit ET-1 synthesis [30]. Rats with remnant
kidney given vehicle exhibited reduced urinary cGMP
levels that were almost doubled by AVE7688. NEP inhi-
bition has been found to increase intrarenal ANP, lead-
ing to the stimulation of particulate guanylate cyclase, in
turn causing an increase in intracellular and extracellu-
lar cGMP that is excreted in the urine [20, 31]. We sug-
gest that the enhanced benefits observed with AVE7688
are due in part to tubular protection conferred by in-
creased renal ANP, as documented by less tubular dam-
age, dilation, and casts than in enalapril-treated animals.
Studies have indicated that delivery of ANP in proxi-
mal tubular cells could stimulate NO production respon-
sible for protective action [32]. This is consistent with our
findings of increased renal synthesis of NO, documented
by the indirect measurement of urinary nitrite/nitrate in
fasted AVE7688-treated animals. The effect of AVE7688
on renal NO production was more remarkable than that
observed with enalapril. Previous studies have demon-
strated that omapatrilat, compared to captopril, com-
pletely restored renovascular endothelial function by
improving NO-mediated relaxation, and normalizing
ECE activity in a model of salt-induced hypertension
[33]. Evidence is available to indicate that stimulation
of renal NO production could occur through bradykinin,
a potent vasoactive peptide that mediates some of the
vasodilatory effects of the vasopeptidase inhibitors [34].
Contemporary inhibition of ACE and NEP by AVE7688
might result in high levels of bradykinin because both en-
zymes are responsible for its degradation, with NEP being
the major route of bradykinin catabolism in the kidney
[35].
CONCLUSION
The present study shows that in the remnant kid-
ney model, the administration of vasopeptidase inhibitor
AVE7688 at the stage of overt nephropathy reduced pro-
teinuria and lessened renal damage better than enalapril
at doses that afforded a comparable blood pressure con-
trol. Vasopeptidase inhibitors, by blocking NEP, interfere
more than ACE inhibitors with the renal generation of
vasoactive mediators. Within the limitation of an obser-
vational study, the fact that AVE7688 corrected the im-
balanced ratio between the vasoconstrictor ET-1 and the
vasodilators NO and ANP in rats with remnant kidney
better than enalapril would suggest this as one of the
mechanisms responsible for the superior renoprotection
of vasopeptidase over ACE inhibitors.
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